# **UNITED STATES** SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

# **SCHEDULE 13G**

	Under the Securities Exchange Act of 1934  (Amendment No)*
	Stellar Biotechnologies Inc.
	(Name of Issuer)
	Common Stock, no par value
	(Title of Class of Securities)
	85855A 10 4
	(CUSIP Number)
	September 9, 2013
	(Date of Event which Requires Filing of this Statement)
Check the appropriat	te box to designate the rule to which this Schedule is filed:
o Rule 1	3d-1 (b)
☑ Rule 1	3d-1 (c)
o Rule 1	3d-1 (d)
* The remainder of the	is cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of subsequent amendment containing information which would alter disclosures provided in a prior cover page.
securities, and for any	subsequent amenument containing information which would after disclosures provided in a prior cover page.
	red on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities
Act (however, see the 1	("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Notes).
1 NAMES OF R	EPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Amaran Bioteo	rhnology Inc
2 CHECK THE (see instruction	APPROPRIATE BOX IF A MEMBER OF A GROUP
$\begin{array}{c c} (\text{see instruction} \\ (\text{a}) & \square & (\text{b}) \end{array}$	
2 CECLICE ON	
3 SEC USE ONI	JY
4 CITIZENSHIP	OR PLACE OF ORGANIZATION
Taiwan (R.O.C	
,	
NUMBER OF SHARES	5 SOLE VOTING POWER
BENEFICIALLY	7,142,858 (4,761,905 common shares and 2,380,953 warrants*)
OWNED BY EACH REPORTING	6 SHARED VOTING POWER
PERSON WITH	
	N/A
	7 SOLE DISPOSITIVE POWER
	7,142,858 (4,761,905 common shares and 2,380,953 warrants*)
	7,142,000 (4,701,500 COMMION SHARES AND 2,300,300 WAITAINS)
	8 SHARED DISPOSITIVE POWER

9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
	7,142,858 (4,761,905 common shares and 2,380,953 warrants*)
	, ,, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
10	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)
10	CILER II THE AGGREGATE AMOUNT IN NOW (5) EXCEODES CERTAIN STRACES (See instructions)
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
	10.19%, assuming exercise of the 2,380,953 warrants of Stellar held by Amaran
12	TYPE OF REPORTING PERSON (see instructions)
12	TITE OF REPORTING PERSON (See instructions)
	CO

#### Item 1(a). Name of Issuer:

Stellar Biotechnologies, Inc.

# Item 1(b) Address of Issuer's Principal Executive Offices:

332 E. Scott Street Port Hueneme, CA 93041

# Item 2(a). Name of Person Filing:

Amaran Biotechology Inc.

# Item 2(b). Address of Principal Business Office or, if None, Residence:

11F-1, No. 308, Sec. 2 BaDe Road, ZhongShan District Taipei City, 10492 Taiwan (R.O.C.)

# Item 2(c). Citizenship:

Amaran Biotechnologies Inc. is a Taiwan (R.O.C.) Corporation

# Item 2(d). Title of Class of Securities:

Common Stock, no par value

### Item 2(e). CUSIP No.:

85855A 10 4

#### Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not applicable

#### Item 4. Ownership

(a) Amount beneficially owned: warrants)

7,142,858 (4,761,905 common shares and 2,380,953

(b) Percent of Class:

10.19%

<sup>\*</sup> On September 9, 2013, Amaran acquired beneficial ownership and control of 4,761,905 common shares and 2,380,953 common stock purchase warrants. The securities were acquired pursuant to a private placement of 4,761,905 common stock units at a price of \$1.05 per unit, with each unit consisting of one common share and one half of a share purchase warrant. Each full warrant entitles the holder to purchase one additional share of Stellar's common stock at a purchase price of US\$1.35 for a period of three years from the issuance date of the warrants. Concurrent with the private placement, Amaran executed a lock-up agreement wherein they agreed, subject to certain exceptions, not to sell the securities of Stellar acquired pursuant to the private placement for a period of 18 months from closing.

# (c) Number of shares to which each person has:

(i) Sole power to vote or direct the vote: 7,142,858 (4,761,905 common shares and 2,380,953 warrants)

(ii) Shared power to vote or direct the vote:

(iii) Sole power to dispose or to direct the disposition of:

N/A 7,142,858 (4,761,905 common shares and 2,380,953

warrants)

(iv) Shared power to dispose or to direct the disposition of: N/A

#### Item 5. Ownership of Five Percent or Less of a Class:

Not Applicable

# Item 6. Ownership of More than Five Percent on Behalf of Another Person:

Not Applicable

# Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

Not Applicable

# Item 8. Identification and Classification of Members of the Group:

Not Applicable

# Item 9. Notice of Dissolution of Group:

Not Applicable

#### Item 10. Certification:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

# **SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Amaran Biotechnology Inc.

Date: September 23, 2013

Signed /s/ "Tessie Che"

Tessie Che,

Chair of the Board of Directors